Saturday 17 October 2026
Export CARL’s income statement to Excel — free account
Carlsmed, Inc.
CARL Healthcare Health Information Services
Carlsmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50.5 million, up 85.9% from fiscal 2024. In the quarter to June 2026, revenue grew 56.8%, EPS grew 73.5%, free cash flow fell 6.84% and total debt was flat, each against the same quarter a year earlier.
13.41
0.54
−3.87%
Follow CARL
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
Altman Z-Score |
— | 2.94 |
P/S ratio |
1.90 | 3.48 |
Altman Z″-Score (non-manufacturers) |
(1.45) | 4.88 |
P/FCF ratio |
0.00 | 0.00 |
P/Operating CF |
(9.45) | (33.01) |
Beneish M-Score |
— | (1.77) |
P/B ratio |
0.00 | 1.78 |
Price to Tangible BV |
0.00 | 1.78 |
EV/Sales |
1.39 | 1.61 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(1.79) | (2.80) |
EV/FCF |
(1.74) | (2.67) |
Quick Ratio |
5.33 | 8.49 |
Current Ratio |
5.60 | 8.87 |
Net Debt/EBITDA |
1.03 | 3.12 |
Debt/Assets |
29.74% | 11.79% |
Debt/Equity |
0.60 | 0.16 |
Asset Turnover |
0.00 | 0.56 |
Operating CF/Net income |
1.02 | 0.96 |
Capex/Depreciation |
(1.24) | (4.83) |
Interest Coverage |
(18.26) | (21.38) |
| 0.00% | (214.02%) | |
| 0.00% | (33.22%) | |
ROIC |
(1,920.54%) | (442.13%) |
Return on Tangible Assets |
(60.91%) | (26.53%) |
Average Days of Receivables |
90.91 | 82.10 |
Research and Development Expense of Revenue |
52.66% | 33.69% |
Selling, General and Administrative Expense of Revenue |
109.94% | 102.15% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.93% | 3.82% |
Graham Net Nets |
0.28 | 0.54 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(44.13%) | (29.64%) |
Free Cash Flow Yield |
(41.89%) | (17.27%) |
Revenue per Share |
6.68 | 3.55 |
Operating CF per Share |
(6.26) | (2.04) |
Capex per Share |
(0.04) | (0.10) |
Free Cash Flow per Share |
(6.31) | (2.13) |
Cash per Share |
9.89 | 7.73 |
Shareholders Equity per Share |
6.29 | 6.95 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
6.29 | 6.95 |
Free Cash Flow |
(25.65) | (30.33) |
Working Capital |
40.53 | 112.39 |
Capital Expenditures |
(0.18) | (1.36) |
Net Current Asset Value |
23.12 | 95.42 |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.01 | 0.03 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.56 | 0.19 |
Cash ROIC |
(31.57%) | (13.54%) |
Accounts Receivable Turnover |
0.00 | 5.57 |
Accounts Payable Turnover |
0.00 | 3.62 |
Inventory Turnover |
0.00 | 8.78 |
Average Days of Payables |
123.70 | 131.15 |
Days of Inventory on Hand |
51.03 | 54.00 |
Average Receivables |
— | 9.06 |
Average Payables |
— | 3.45 |
Average Inventory |
— | 1.42 |
Average Assets |
— | 90.97 |
Average Common Equity |
— | 14.12 |
Columns are period end dates